Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2015

View Archived Issues

Vitae Pharmaceuticals gives details on discovery of LXRbeta agonist

First inhalable prostacyclin IP receptor agonist for pulmonary arterial hypertension

Astellas Pharma begins phase Ib/II study of ASP-2215 in combination with erlotinib

FDA grants fast track designation to CF-301

R-Pharm acquires Ixempra from Bristol-Myers Squibb

Cadila Healthcare patents kappa-opioid receptor agonists

GlaxoSmithKline reports development of LRRK2 inhibitors

Roche describes HBsAg secretion inhibitors

AVEO forms license agreement with Novartis for AV-380 and related antibodies

CSIR scientists develop agents for treatment of tuberculosis

Ono Pharmaceutical synthesizes GABA(A) receptor alpha5 subunit NAMs

Health Canada approves Strensiq for hypophosphatasia

Phase II trial of oral CR-845 begins in osteoarthritis

Phase Ib modified diet trial achieves primary objective in Duchenne muscular dystrophy

European Commission grants marketing authorization to Unituxin

A novel modified glycosaminoglycan shows efficacy for mouth disorders

SymBio updates on clinical trials of rigosertib and azacitidine in MDS and AML

Spectrum Pharmaceuticals gains FDA agreement on requirements for apaziquone NDA filing

Pfenex wins BARDA contract to develop anthrax vaccine

FDA accepts NDA filing for octreotide

FDA accepts NDA for dronabinol oral solution for CINV- and AIDS-associated anorexia

Retrotope starts recruitment in phase I/II trial of RT-001 in Friedreich's ataxia

AstraZeneca positions antitumor compound AZD-4320 for clinical development

FDA approves Procysbi for children aged 2-6 years with nephropathic cystinosis

Novel alpha7 nACh receptor partial agonist shows potential for use in schizophrenia

Kite Pharma's KTE-C19 reports on phase I portion of NHL trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...